Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Millan v. Schoeneck et al
Case Number:
3:21-cv-05871
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Derivative Litigation
Judge:
Firms
Companies
Sectors & Industries:
-
January 31, 2024
FibroGen's $28.5M Deal With 30K Investors Nears Tentative OK
A California federal judge indicated Wednesday that he'll preliminarily sign off on a $28.5 million settlement secured for a class of approximately 30,000 FibroGen investors who accused the company of making misleading statements about the safety of its anemia drug, citing the risk of recoverability issues due to FibroGen's financial state.
-
July 18, 2022
FibroGen Can't Dodge Securities Suit Over Anemia Drug
FibroGen Inc. can't escape a securities fraud class action over the flop of a once-hyped anemia drug, as a California judge ruled the investors plausibly alleged that the company made misleading statements that affected the value of the company's stocks.